Bayer Faces a Split-Screen Quarter: Slashed Profit Forecasts on One Side, a Courtroom Breakthrough on the Other
Published on 11/02/2026 at 17:10 | Editorial boerse-global.de
Bayer investors are heading into the November 3 third-quarter report with a paradox on their hands. The earnings bar has been lowered sharply over the past month, yet the company's legal overhang just produced its first genuinely encouraging courtroom signal since the US Supreme Court weighed in this summer.
Consensus now looks for earnings per share of €0.42 on revenue of €10.00 billion when the quarterly statement lands at 07:30 CET, ahead of the opening bell. The investor video call follows at 14:00 CET. What makes the setup unusual is the divergence inside those numbers: revenue estimates have barely budged, while EPS forecasts have been cut by 28.14% over the past 30 days. A stable top line, in other words, has not carried through to the bottom line.
JPMorgan Sticks to Its Call
Richard Vosser at JPMorgan reaffirmed an "Overweight" rating and a €61 price target on Friday, framing the defense verdict in Missouri as one more step toward containing the litigation. Jefferies took a cooler view the same day. Michael Leuchten kept a "Hold" and a €46 target, calling the first glyphosate trial win since the Supreme Court's June ruling encouraging but pointing to the same missing piece both analysts flagged: the judge has yet to sign off on the proposed settlement.
The verdict itself came in the case of Theresa Aretino et al., where a Missouri jury ruled unanimously for Monsanto, according to Bayer. Three plaintiffs had pursued claims of alleged product defects, misrepresentation and negligence. It marked the first glyphosate trial since the June Supreme Court decision, and dpa-AFX identified it as the concrete trigger for the share price move that followed. The stock was giving back 0.5% today.
Should investors sell immediately? Or is it worth buying Bayer?
The Settlement Is Still a Proposal
Roughly 65,000 US Roundup claims remain outstanding. The proposed collective settlement provides for up to $7.25 billion spread over a maximum of 21 years. Final judicial approval is pending, which means that payment envelope cannot be treated as a resolved liability — and even a settlement drawn over two decades would not remove the importance of the operating business to Bayer's financial room to maneuver.
That matters because of the balance sheet. Net financial debt stood at €33.35 billion as of June 30, with the ratio of net debt to EBITDA at 3.2 times. Against that leverage, the earnings trajectory carries unusual weight for shareholders. The quarterly statement is therefore more than a test of short-term profit expectations; it offers a fresh reference point for judging how resilient Bayer's finances are while the legal risks grind on.
Three Pipeline Wins in Quick Succession
The operating side has not stood still. A little over a week ago, China's NMPA approved Asundexian for reducing stroke risk — the first factor XIa inhibitor cleared in China, according to Reuters. Around the same time, interim analysis results from the Phase III DASL-HiCaP study were presented at the ESMO congress, showing darolutamide combined with androgen deprivation therapy and radiotherapy reduced the risk of prostate cancer spread in patients at very high risk of recurrence. On October 2, Bayer announced a $2.2 billion investment in a new pharmaceutical production site in New Albany, Ohio, where it plans roughly 600 new jobs.
Bayer at a turning point? This analysis reveals what investors need to know now.
Whether the lowered bar is low enough will only become clear once the actual figures are published. Revenue and profit deserve to be read separately for that reason, and the guidance attached to the numbers will say as much about financial headroom as the headline EPS does. The open legal questions remain central — but the next hard data point comes from the business itself.
Ad
Bayer Stock: New Analysis - 2 November
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
